An open label, single arm, phase Ib dose finding study of i.v. panobinostat (LBH589) with docetaxel and prednisone in patients with hormone refractory prostate cancer.
Phase of Trial: Phase I
Latest Information Update: 16 May 2012
At a glance
- Drugs Docetaxel; Panobinostat; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- 16 May 2012 Actual end date changed from Han 2012 to Dec 2011 as reported by ClinicalTrials.gov.
- 30 Apr 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 30 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.